Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

236 Clinical Updates found
MSK HPB surgeons
Minimally invasive surgery (MIS) to resect liver segments 7 and 8 is safe for select patients treated by experienced MIS hepatopancreatobiliary surgeons.
Dr. Mark Bilsky with a patient
Surgical resection of symptomatic, benign intradural extramedullary (IDEM) spine tumors provides rapid, significant, and durable improvements in patient-reported outcomes.
David Solit, MD
Clinical Update
At Memorial Sloan Kettering Cancer Center, we have now analyzed more than 50,000 samples in our prospective cohort with MSK-IMPACT™.
Audree B. Tadros
Breast conservation therapy as an initial treatment did not compromise survival outcomes compared to mastectomy in breast cancer patients under the age of 35.
CD4+ T cell
Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease.
Patient is examined at MSK Kids
Patients with choroidal invasion of retinoblastoma can be successfully managed with ophthalmic artery chemosurgery (OAC) and avoid enucleation.
Ilya Laufer
Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Esther Babady
Patients with profound immunosuppression after undergoing hematopoietic stem-cell transplantation or receiving chimeric antigen receptor (CAR) T cell therapy may shed viable SARS-CoV-2 for at least two months.
Dr. Long Roche with a patient
Receiving five or more cycles of neoadjuvant chemotherapy was associated with worse progression-free survival (PFS) and overall survival (OS) compared to receiving three or four cycles — despite maximal surgical cytoreduction.
Robert Motzer
Everolimus plus bevacizumab demonstrates robust activity in treatment-naïve patients with advanced papillary variant nonclear cell renal cell carcinoma.